Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | TACR1 | P25103 | 8/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | USP14 | P54578 | 2/20 | 0.34 |
| ▸ | USP7 | Q93009 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | USP5 | P45974 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5746450 | 0.75 | MEN1 (0.39) | TACR1SIGMAR1 | |
| SCHEMBL5745280 | 0.73 | TACR1 (0.37) | TACR1OPRL1 | |
| SCHEMBL6311508 | 0.72 | KDM4E (0.41) | KDM4ETACR1POLBPKMUSP14 | |
| SCHEMBL6064290 | 0.69 | TACR1 (0.54) | TACR1 | |
| SCHEMBL6064294 | 0.69 | TACR1 (0.54) | TACR1 | |
| SCHEMBL6550098 | 0.68 | TACR1 (0.53) | TACR1 | |
| SCHEMBL6309911 | 0.68 | TACR1 (0.41) | KDM4ETACR1OPRL1SLC6A1 | |
| SCHEMBL6309919 | 0.68 | TACR1 (0.41) | KDM4ETACR1OPRL1SLC6A1 | |
| SCHEMBL5619397 | 0.67 | TACR1 (0.39) | TACR1POLBOPRL1 | |
| SCHEMBL6397911 | 0.67 | TACR1 (0.41) | KDM4ETACR1HPGDOPRL1SLC6A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043354-A1 | NK1 antagonist | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043354-A1 | NK1 antagonist | TACR2, TACR1, TAC3 | KDM4E 1833/4885TACR1 2/4885POLB 4702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.